Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma

Neurosurgical Focus

Volumn 38, Issue 3, 2015, Pages

  Caruso, James P ^a   Cohen Inbar, Or ^a,f   Bilsky, Mark H ^b,c   Gerszten, Peter C ^d   Sheehan, Jason P ^a,e  

^a UNIVERSITY OF VIRGINIA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Immunotherapy; Metastatic spinal melanoma; Review; Separation surgery; Stereotactic radiosurgery

Indexed keywords

HUMAN; IMMUNOTHERAPY; MELANOMA; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; RADIOSURGERY; SECONDARY; SPINAL NEOPLASMS; TUMOR RECURRENCE;

HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM RECURRENCE, LOCAL; RADIOSURGERY; SPINAL NEOPLASMS;

EID: 84929645757     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2014.11.FOCUS14716     Document Type: Article

References (94)

1. Adler JR Jr, Muacevic A, Romanelli P: CyberKnife radiosurgery, in Chin LS, Regine WF (eds): Principles and Practice of Stereotactic Radiosurgery. New York: Springer, 2008, pp 171-178.
2. Ahmed KA, Stauder MC, Miller RC, Bauer HJ, Rose PS, Olivier KR, et al: Stereotactic body radiation therapy in spinal metastases. Int J Radiat Oncol Biol Phys 82:e803-e809, 2012.
3. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105-2116, 1999.
4. Baker PK, Pettitt AR, Slupsky JR, Chen HJ, Glenn MA, Zuzel M, et al: Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion. Blood 100:647-653, 2002.
5. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001.
6. Bedrosian I, Faries MB, Guerry D IV, Elenitsas R, Schuchter L, Mick R, et al: Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol 7:262-267, 2000.
7. Biron CA: Interferons alpha and beta as immune regulators-a new look. Immunity 14:661-664, 2001.
8. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599, 2010.
9. Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al: Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 11:873-886, 2012.
10. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012.
11. Bydon M, De la Garza-Ramos R, Bettagowda C, Gokaslan ZL, Sciubba DM: The use of stereotactic radiosurgery for the treatment of spinal axis tumors: a review. Clin Neurol Neurosurg 125:166-172, 2014.
12. Carpi A, Nicolini A, Antonelli A, Ferrari P, Rossi G: Cytokines in the management of high risk or advanced breast cancer: an update and expectation. Curr Cancer Drug Targets 9:888-903, 2009.
13. Cattell E, Kelly C, Middleton MR: Brain metastases in melanoma: a European perspective. Semin Oncol 29:513-517, 2002.
14. Chan NK, Abdullah KG, Lubelski D, Steinmetz MP, Benzel EC, Shin JH, et al: Stereotactic radiosurgery for metastatic spine tumors. J Neurosurg Sci 58:37-44, 2014.
15. Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu XY: Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 17:5328-5337, 1997.
16. Chu MB, Fesler MJ, Armbrecht ES, Fosko SW, Hsueh E, Richart JM: High-Dose Interleukin-2 (HD IL-2) therapy should be considered for treatment of patients with melanoma brain metastases. Chemother Res Pract 2013:726925, 2013.
17. Cloyd JM, Acosta FL Jr, Polley MY, Ames CP: En bloc resection for primary and metastatic tumors of the spine: a systematic review of the literature. Neurosurgery 67:435-445, 2010.
18. Conill C, Jorcano S, Domingo-Domènech J, Marruecos J, Vilella R, Malvehy J, et al: Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients. Melanoma Res 17:304-309, 2007.
19. Demaria S, Bhardwaj N, McBride WH, Formenti SC: Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 63:655-666, 2005.
20. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11:728-734, 2005.
21. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al: Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15:5379-5388, 2009.
22. Egen JG, Allison JP: Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16:23-35, 2002.
23. Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met Ö, et al: Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med 10:169, 2012.
24. Evrard S, Menetrier-Caux C, Biota C, Neaud V, Mathoulin-Pélissier S, Blay JY, et al: Cytokines pattern after surgical radiofrequency ablation of liver colorectal metastases. Gastroenterol Clin Biol 31:141-145, 2007.
25. Finkelstein SE, Trotti A, Rao N, Reintgen D, Cruse W, Feun L, et al: The Florida Melanoma Trial I: a prospective multicenter phase I/II trial of postoperative hypofractionated adjuvant radiotherapy with concurrent interferon-Alfa-2b in the treatment of advanced stage III melanoma with long-term toxicity follow-up. ISRN Immunology 2012:324235, 2012.
26. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM: Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16:5-24, 2011.
27. Gerszten PC, Burton SA, Ozhasoglu C, Welch WC: Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976) 32:193-199, 2007.
28. Gerszten PC, Burton SA, Quinn AE, Agarwala SS, Kirkwood JM: Radiosurgery for the treatment of spinal melanoma metastases. Stereotact Funct Neurosurg 83:213-221, 2005.
29. Gokaslan ZL, Aladag MA, Ellerhorst JA: Melanoma metastatic to the spine: a review of 133 cases. Melanoma Res 10:78-80, 2000.
30. Guckenberger M, Mantel F, Gerszten PC, Flickinger JC, Sahgal A, Létourneau D, et al: Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiat Oncol 9:226, 2014.
31. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-144, 2013.
32. Harel R, Zach L: Spine radiosurgery for spinal metastases: indications, technique and outcome. Neurol Res 36:550-556, 2014.
33. Hazard LJ, Sause WT, Noyes RD: Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity. Int J Radiat Oncol Biol Phys 52:796-800, 2002.
34. Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, et al: CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 5:557-561, 2008.
35. Huang S, Bucana CD, Van Arsdall M, Fidler IJ: Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 21:2504-2512, 2002.
36. Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, et al: Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother 34:212-220, 2011.
37. Jahanshahi P, Nasr N, Unger K, Batouli A, Gagnon GJ: Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management. Front Oncol 2:167, 2012.
38. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010.
39. Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, et al: Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J 6:139-145, 2000.
40. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, et al: The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 10:588-598, 2013.
41. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL: Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117:227-233, 2012.
42. Ku A, Henry A, Tunkel R, Lachmann E, Nagler W: Lumbosacral radiculopathy secondary to L5 metastatic melanoma of unknown primary. Arch Phys Med Rehabil 77:307-309, 1996.
43. Laufer I, Iorgulescu JB, Chapman T, Lis E, Shi W, Zhang Z, et al: Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or highdose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients. J Neurosurg Spine 18:207-214, 2013.
44. Laufer I, Rubin DG, Lis E, Cox BW, Stubblefield MD, Yamada Y, et al: The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist 18:744-751, 2013.
45. Legha SS: Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.Semin Oncol 24 (1 Suppl 4):S39-S43, 1997.
46. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793-801, 1994.
47. Lippitz B, Lindquist C, Paddick I, Peterson D, O'Neill K, Beaney R: Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. Cancer Treat Rev 40:48-59, 2014.
48. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087-1095, 2012.
49. McWilliams RR, Rao RD, Buckner JC, Link MJ, Markovic S, Brown PD: Melanoma-induced brain metastases. Expert Rev Anticancer Ther 8:743-755, 2008.
50. Moussazadeh N, Laufer I, Yamada Y, Bilsky MH: Separation surgery for spinal metastases: effect of spinal radiosurgery on surgical treatment goals. Cancer Contr 21:168-174, 2014.
51. Myint AM, Schwarz MJ, Steinbusch HW, Leonard BE: Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis 24:55-68, 2009.
52. Napoletano C, Taurino F, Biffoni M, De Majo A, Coscarella G, Bellati F, et al: RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol 32:481-490, 2008.
53. Nguyen NP, Levinson B, Dutta S, Karlsson U, Alfieri A, Childress C, et al: Concurrent interferon-alpha and radiation for head and neck melanoma. Melanoma Res 13:67-71, 2003.
54. Nicholas C, Lesinski GB: Immunomodulatory cytokines as therapeutic agents for melanoma. Immunotherapy 3:673-690, 2011.
55. O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, et al: Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 3:1378-1393, 2013.
56. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 21:1712-1717, 2010.
57. Okazaki T, Honjo T: The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 27:195-201, 2006.
58. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252-264, 2012.
59. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al: CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25:9543-9553, 2005.
60. Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, et al: Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366:643-648, 2005.
61. Phan GQ, Rosenberg SA: Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Contr 20:289-297, 2013.
62. Plosker GL: Interferon-β-1b: a review of its use in multiple sclerosis. CNS Drugs 25:67-88, 2011.
63. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al: Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366:925-931, 2012.
64. Powell S, Dudek AZ: Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res 29:4189-4193, 2009.
65. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al: CTLA-4 blockade with ipilimumab: longterm follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039-2047, 2012.
66. Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, et al: Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res 9:84-92, 2003.
67. Reed KB, Brewer JD, Lohse CM, Bringe KE, Pruitt CN, Gibson LE: Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc 87:328-334, 2012.
68. Richtig E, Langmann G, Schlemmer G, Müllner K, Papaefthymiou G, Bergthaler P, et al: [Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma.] Ophthalmologe 103:506-511, 2006 (Ger).
69. Riley JL, Mao M, Kobayashi S, Biery M, Burchard J, Cavet G, et al: Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci U S A 99:11790-11795, 2002.
70. Rosberger DF, Coleman DJ, Silverman R, Woods S, Rondeau M, Cunningham-Rundles S: Immunomodulation in choroidal melanoma: reversal of inverted CD4/CD8 ratios following treatment with ultrasonic hyperthermia. Biotechnol Ther 5:59-68, 1994.
71. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166, 1994.
72. Sahgal A, Larson DA, Chang EL: Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys 71:652-665, 2008.
73. Sahgal A, Whyne CM, Ma L, Larson DA, Fehlings MG: Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. Lancet Oncol 14:e310-e320, 2013.
74. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al: Reversal of the TCR stop signal by CTLA-4. Science 313:1972-1975, 2006.
75. Schneider H, Mandelbrot DA, Greenwald RJ, Ng F, Lechler R, Sharpe AH, et al: Cutting edge: CTLA-4 (CD152) differentially regulates mitogen-activated protein kinases (extracellular signal-regulated kinase and c-Jun N-terminal kinase) in CD4+ T cells from receptor/ligand-deficient mice. J Immunol 169:3475-3479, 2002.
76. Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B, et al: Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 89:957-964, 1997.
77. Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, et al: Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunological responses. SciTransl Med 4:137ra174, 2012.
78. Shah DJ, Dronca RS: Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc 89:504-519, 2014.
79. Song CW, Kim MS, Cho LC, Dusenbery K, Sperduto PW: Radiobiological basis of SBRT and SRS. Int J Clin Oncol 19:570-578, 2014.
80. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL: Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 52:1251-1257, 2010.
81. Stewart WR, Gelberman RH, Harrelson JM, Seigler HF: Skeletal metastases of melanoma. J Bone Joint Surg Am 60:645-649, 1978.
82. Thiagaragan A, Yamada Y, Lovelock DM, Cox BW, Zelefsky MJ, Bilsky M: Stereotactic radiosurgery: a new paradigm for melanoma and renal cell carcinoma spine metastases. J Clin Oncol 28 (Suppl):2030, 2010 (Abstract).
83. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T: Surgical strategy for spinal metastases. Spine (Phila Pa 1976) 26:298-306, 2001.
84. Topalian SL, Drake CG, Pardoll DM: Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24:207-212, 2012.
85. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012.
86. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020-1030, 2014.
87. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105:3041-3046, 2008.
88. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, et al: B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 193:839-846, 2001.
89. van der Linden YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW: Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer 103:320-328, 2005.
90. Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C: White paper on adoptive cell therapy for cancer with tumorinfiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 17:1664-1673, 2011.
91. Weber JS, Amin A, Minor D, Siegel J, Berman D, O'Day SJ: Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 21:530-534, 2011.
92. Wouters J, Stas M, Gremeaux L, Govaere O, Van den Broeck A, Maes H, et al: The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis. PLoS ONE 8:e76550, 2013.
93. Wu F: High intensity focused ultrasound ablation and antitumor immune response. J Acoust Soc Am 134:1695-1701, 2013.
94. Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, Johnson J, et al: High-dose, single-fraction imageguided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 71:484-490, 2008.